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Abstract The purpose of this study was to assess the one-
year efficacy of highly active antiretroviral therapy
(HAART) administered by general practitioners in a
primary care community clinic in rural South Africa. We
performed an observational cohort study of 675 treatment-
naïve human immunodeficiency virus (HIV)-infected
patients (including 66 children) who began HAART at
least 12 months prior to the data analyses. Throughout
treatment, the CD4+ T-cell count (percentage of CD4+ T-
cells in children) and plasma HIV-RNA level were
determined and the patient’s weight was recorded. The
primary outcome was mortality. Secondary outcomes were
viral suppression, immunological response, and weight
gain. One year after the start of HAART, 100 of the 675
(15%) patients were lost to follow-up and 119 patients
(18%), including six children, died. Mortality was highest
during the first few months of treatment. Based on an on-
treatment analysis at one year after the start of therapy, 83%
of adults and 71% of children had a viral load <400 copies/
ml; the viral load was <50 copies/ml in 70% of adults and
61% of children. At one year, the mean CD4+ T-cell count
in adults had increased by 236/mm3, and the mean body
mass index (BMI) had increased by 3.5 kg/m2. In children,
the mean CD4% had increased by 17.6. A low Karnofsky
score and a low baseline CD4+ T-cell count were
independently associated with death. In addition to these
factors, a low baseline BMI and gender were predictive of a
poor immunological outcome. Our study shows that
adequately monitored HIV/acquired immunodeficiency
syndrome (AIDS) care administered by general practi-
tioners and their staff is feasible and leads to good results in
a rural, primary care center in sub-Saharan Africa. In order
to achieve even better results, early mortality should be
reduced and efforts should be made to start HAART earlier.
Introduction
Highly active antiretroviral therapy (HAART) is acknowl-
edged worldwide as the standard of care for people with
human immunodeficiency virus/acquired immunodeficien-
cy syndrome (HIV/AIDS) [1–3]. It decreases plasma HIV-
RNA levels, increases CD4+ T-cell counts, decreases
morbidity, and prolongs survival in HIV-infected patients
[4, 5]. Several studies have shown that HAART can be
applied with the same efficacy in developing and developed
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countries [6–11]. However, concerns about the lack of
infrastructure, irregular medication supply, and poor adher-
ence has led to pessimism about the feasibility of HAART
programs in resource-constrained settings. Figures from the
World Health Organization (WHO) show that only 17% of
people who need HAART in sub-Saharan Africa actually
receive it [12]. The failure of initial antiretroviral regimens
and the emergence of widespread antiretroviral drug
resistance, which would reduce the long-term durability of
HAART in developing countries, is a serious concern.
The implementation of HAART in rural areas of resource-
limited countries can be hazardous. This observational study
reports on the one-year efficacy of HAART in a sub-Saharan,
rural setting in 675 consecutive patients who were initiated
antiretroviral therapy from September 2003 through April
2006. The patients were treated in a primary care setting and
the treatment was administered and monitored by general
practitioners. In addition to clinical and immunological data,
longitudinal viral load testing was also performed.
Methods
Site and patients
Elandsdoorn is a township with an estimated population of
40,000. It is situated in a poor, rural area in Mpumalanga, a
province in the northeast of the Republic of South Africa.
AIDS is the leading cause of death in adults in South
Africa, and it is estimated that about 48% of deaths are
related to HIV [13]. In a Mpumalanga-based study, the HIV
prevalence among adults aged 15 to 49 years was 23.1%
[14]. Among antenatal clinic attendees, HIV prevalence
was 30.8% [15].
The Ndlovu Medical Centre is a non-governmental
organization in Elandsdoorn (http://www.elandsdoorn.com/)
that provides “paid for service” primary health care, as well
as prevention-, tuberculosis-, and HIV/AIDS-programs
which are donor-funded and free of charge for the patient.
During the study period, five general practitioners were
in charge of running the outpatient clinic. The clinic has a
maternity ward with 16 beds. Some of these beds can also
be used for HIV/AIDS patients. The clinic is equipped with
X-ray and ultrasound equipment, a pharmacy, and a
laboratory with facilities to perform CD4+ T-cell counts,
plasma HIV-RNA analysis, full blood counts, and blood
chemistry investigations. In 2003, a privately subsidized
program for the provision of HAART was initiated.
In accordance with the WHO guidelines, adults were
eligible for antiretroviral therapy if they had a WHO stage
IV AIDS-defining illness, irrespective of their CD4+ T-cell
count, or if their CD4+ T-cell count was below 200/mm3,
irrespective of their clinical stage [1, 2]. Children were
eligible if they had a WHO stage C disease or a CD4
percentage of less than 15 [1, 3].
Patients could enroll in the program if they lived within a
25-km radius of the clinic. To optimize adherence, a
number of psychosocial conditions were established for
inclusion: (1) disclosure of HIV status to at least one
relative or friend who had to accompany the patient to the
clinic when he/she came for information and counseling;
(2) a relative or friend willing to support the patient in
treatment adherence (family and friends assisted treatment
adherence; FAST); and (3) demonstrated reliability, i.e., the
patient had attended three or more scheduled visits to the
clinic over a three-month period. The final decision to treat
was ascertained by a multidisciplinary team including both
community members and the caregiver. During HAART,
the patients were seen by a doctor and counselor every two
weeks for the first two months and monthly thereafter. The
counselors completed questionnaires on employment,
means of income, education, and household structures
when the patients entered the program.
Antiretroviral therapy was in accordance with the
national guidelines [16]. Unless contraindicated, all patients
(children and adults) started therapy with stavudine (d4T,
40 mg bid or 30 mg bid if their weight was less than 60 kg),
lamivudine (3TC, 150 mg bid), and efavirenz (EFV,
600 mg qd) or nevirapin (NVP, 200 mg bid). All drugs
were administered separately, as triomune was not avail-
able. Later, during the inclusion period, patients often
began receiving Combivir combined with either nevirapin
or efavirenz. Young children were given syrups and older
children were given tablets. The dosage depended on the
child’s weight.
For second-line treatment, non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs) could be switched to the
protease inhibitors (PIs) lopinavir/ritonavir. The efavirenz
dose was not adjusted during treatment with rifampin. HIV-
infected patients with pulmonary tuberculosis and a CD4+
T-cell count higher than 200 /mm3 were treated for
tuberculosis, and antiretroviral therapy was deferred until
they met the WHO criteria. In patients with tuberculosis
and a CD4+ T-cell count of less than 200/mm3, antire-
troviral therapy was initiated after the completion of two
months of tuberculosis therapy or, simultaneously, depend-
ing on the clinical status of the patient.
The counselors monitored adherence to HAART during
the patients’ visits to the clinic and during home visits. If
necessary, the patients received funds to cover the cost of
transport to the clinic and food parcels.
Data collection
Data were retrospectively collected from the medical charts.
Patients entered the program from September 2003 through
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April 2006, by definition, at least 12 months before the data
analyses, and were all treatment-naïve when starting
HAART. The clinic also treats pregnant women according
to the prevention of mother-to-child transmission (pMTCT)
protocol. Data from the pMTCT program were not included
in this study, as inclusion of the pMTCT recipients would
make the study population more heterogeneous.
Adults’ body mass indices (BMI, weight/height2) and
children’s weights were recorded during each visit. The
Karnofsky performance score and the WHO staging
system were used to establish the patient’s clinical
condition when HAART was initiated. At baseline, the
CD4+ T-cell count (FACSCount system, Becton Dickinson
Biosciences, San Jose, CA), the plasma HIV-RNA level
(System 340 bDNA analyzer, Bayer AG, Leverkusen,
Germany), and a full blood count were measured, and at 6,
12, 24, 36, and 52 weeks, the plasma HIV-RNA level,
CD4+ T-cell count (CD4% in children), full blood count,
and alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), creatinin, urea, and amylase concentrations
were measured.
Statistical analysis
The data were analyzed on both an intention-to-treat (ITT)
and an on-treatment (OT) basis. The primary endpoint was
mortality from all causes during the first year after starting
HAART. Secondary endpoints were the proportion of
patients with a viral load of less than 50 and less than
400 copies/ml, good immunological response as defined by
a CD4+ T-cell count higher than 200/mm3 or a CD4% of 15
or higher in children, and an increase in BMI or weight. We
ignored treatment changes and interruptions.
To define predictors of treatment efficacy, we compared
the outcome (survival and immunological response) of
adult patients who presented a poor clinical condition at
baseline, as defined by a BMI in the lowest quartile, a
Karnofsky score of 50 or less, and a CD4+ T-cell count of
50/mm3 or less, with that of patients who were in better
condition.
Continuous data were compared with Student’s t-test
or the paired t-test, as appropriate. Proportions were
compared with the χ2 test, and data that were not normally
distributed were analyzed via the Mann-Whitney U-test or
Wilcoxon’s test. Kaplan-Meier survival analyses were
used to estimate the time from the initiation of antire-
troviral therapy to viral suppression and good immuno-
logic response. Odds ratios were calculated using logistic
regression analysis. The Cox proportional-hazards model
was used to identify independent predictors of the
endpoints. To this end, a multivariate analysis was
performed for all variables that were significant (p<0.10)
in the univariate analysis.
Results
Patient characteristics
Between September 2003 and May 2006, the Ndlovu
Medical Center provided HIV voluntary counseling and
testing (VCT) to 5,226 patients, of whom 2,442 (47%) were
tested as HIV seropositive (Fig. 1). Of these, 675 (28%)
started antiretroviral therapy and were included in our
analysis; 609 (90%) were adults (age range 16 to 73 years)
and 66 (10%) were children (age range eight months to
11 years). Fifty-four percent of the adults and 77% of the
children were also treated for tuberculosis.
The baseline patient characteristics and initial antiretro-
viral therapy regimens of the adults and children are
summarized in Table 1. At presentation, 32 patients (5%)
were too weak to stand and a BMI could not be calculated.
In the remaining patients, the median BMI was significantly
lower in men (18.6 kg/m2) than in women (20.3 kg/m2,
p<0.01). There was also a significant difference in the
median CD4+ T-cell counts between men and women of
54/mm3 and 74/mm3, respectively (p=0.02). The median
weight of the children at baseline was 13.8 kg. The low
average socio-economic status is shown by the high
unemployment rate among participants and widespread
dependency on government grants.
Patient outcome
At 12 months after HAART initiation, 407 of 609 adults
(67%) and 49 of 66 children (74%) were alive and in care.
Eighty-nine adults (15%) and 11 children (17%) were lost
to follow-up. There was a statistically significant difference
in the baseline CD4+ T-cell counts between patients who
were lost to follow-up and those who were not; 86/mm3
675 (28%) antiretroviral 
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Fig. 1 Cohort profile. HAART=highly active antiretroviral therapy;
m=months; yr=years; ARV=antiretroviral therapy
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Table 1 Patients’ characteristics
Characteristic Adults (n=609) Children (n=66)
Age (SD) 34.9 years (9.0) 57 months (31.3)
Female sex, n (%) 431 (70.8) 33 (50.0)
TB treatment, n (%)
- No TB treatment 281 (46.1) 15 (22.7)
- TB treatment prior to HAART 152 (25.0) 26 (39.4)
- TB treatment during HAART 176 (28.9) 25 (37.9)
BMI, median (inter-quartile range)
- Total adult population 19.6 (17.2–22.6) -
- Men 18.6 (16.8–21.5) -
- Women 20.3 (17.6–23.4) -
Weight, median (range) (kg) 51 (24–94) 13.8 (5.5–23,3)
WHO stage, n (%)
- WHO 1 59 (9.7) -
- WHO 2 63 (10.3) -
- WHO 3 375 (61.6) -
- WHO 4 106 (17.4) -
- Missing 6 (1.0) -
Karnofsky score, n (%)
- ≤50 47 (7.7) -
- >50 560 (92.0) -
- Missing 2 (0.3) -
CD4 T-cell count, median (range) (cell count/mm3)
- Total adult population 67 (1–466) -
- Men 54 (1–466) -
- Women 74 (1–379) -
CD4 percentage, median (range) - 10.6 (0.1–29.8)
10log (baseline viral load)
- Median (range) 5.0 (1.4–5.9) 5.1 (3.0–5.7)
ARV regimen, n (%)
Lamivudine/stavudine/efavirenz 257 (42.2) -
Lamivudine/stavudine/nevirapin 201 (33.0) -
Lamivudine/zidovudine/efavirenz 86 (14.1) 16 (24.2)
Lamivudine/zidovudine/nevirapin 39 (6.4) 50 (75.8)
DDI/stavudine/efavirenz 2 (0.3) -
Combivir/efavirenz 22 (3.6) -
Combivir/nevirapin 2 (0.3) -
*Unemployment rate, n (%) 428 (75.8) -
*Means of income
- None 144 (25.5) -
- Employment 135 (23.9) -
- Money from family member 152 (26.9) -
- Grant 132 (23.4) -
- Missing 2 (0.4) -
*Living with a partner, n (%) 278 (49.2) -
*Number of people in household
- Median (range) 6 (1–16) -
*Education
- None 51 (8.4) -
- Grade 1 to 6 76 (12.5) -
- Grade 7 to 12 425 (69.8) -
- Third level 7 (1.2) -




*=socio-demographic data were known for 565 of 609 adults (93%)
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versus 64/mm3, respectively (p=0.05). Other baseline
characteristics were comparable between these two groups
(data not shown). One hundred and thirteen adults (19%,
Table 2) and six children (9%) died. Of the 113 adult
deaths, 49 (43%) occurred within the first month after the
initiation of HAART and 78 (69%) occurred within the first
two months. Three of the six children passed away during
the first month of HAART.
As most patients died at home, the actual cause of death
was often unknown.
There was no statistically significant difference in
survival between patients who received tuberculosis treat-
ment and those who did not (p=0.7).
Viral load, CD4+ T-cell response, and BMI in adults
No blood samples were available after the baseline sample
in 81 of the 609 (13%) adults: 49/81 died and 32/81 were
lost to follow-up before a second sample could be drawn.
For the remaining 528 patients, on-treatment blood samples
were available as well. A plasma HIV-RNA level lower
than 400 copies/ml in at least one of those blood samples
was seen in 494 of these 528 (94%) patients, and a plasma
HIV-RNA level lower than 50 copies/ml was registered in
439 of 528 patients (83%, Fig. 2).
Longitudinal follow-up of the patients who achieved
viral suppression showed that plasma HIV-RNA levels
remained lower than 400 copies/ml in 400 of 494 (81%)
patients, and lower than 50 copies/ml in 316 of 439 patients
(72%). Virological failure (plasma HIV-RNA >1,000
copies/ml) occurred in 51 patients (10%). No further data
after the initial viral suppression were available for 43 (9%)
patients (Fig. 3).
At one-year follow-up, the plasma HIV-RNA level was
lower than 400 copies/ml in 336 patients (336/609
ITT=55%, 336/407 OT=83%) and lower than 50 copies/
ml in 283 patients (283/609 ITT=46%, 283/407 OT=70%).
The mean increase in the CD4+ T-cell counts was 168/
mm3 (95% CI: 156–179, p<0.001) at week 24 and 236/
mm3 (95% CI: 220–252, p<0.001) at week 52, resulting in
a median CD4+ T-cell count of 297/mm3 (IQR 195–421 /
mm3). Sixty-one percent of adults had a good immunolog-
ical response (CD4 T-cell count >200/mm3) at week 24 and
74% at week 52 (on-treatment analysis).
The mean BMI had increased by 2.4 kg/m2 (p<0.001) at
week 24 and by 3.5 kg/m2 (p<0.001) at week 52, resulting
in a median BMI of 23.4 kg/m2 at week 52.
Viral load, CD4+ T-cell response, and weight in children
Apart from the seven children who either died or were lost
to follow-up before week six, a plasma HIV-RNA level
lower than 400 copies/ml was registered at some time
during therapy in all 59 children, and a level lower than 50




















No at risk:       609    412    209           85            52 
Percentage:        80      44     19           13                 6 
Fig. 2 Kaplan-Meier estimate of the proportion of adult patients with
a plasma HIV-RNA level of more than 50 copies/ml during
antiretroviral therapy
Table 2 Mortality in adults according to CD4 count at baseline
CD4 n Died
0–50 256 70 (27%)
51–100 124 14 (11%)
101–200 188 26 (14%)
>200 38 3 (8%)
Total 606 113
CD4=CD4+ T-cell count at baseline (cell count/mm3 )
n=number of patients who started antiretroviral therapy
NB: CD4 count at baseline was unknown for three patients; these






































Fig. 3 Virological data in adults and children after reaching a plasma
HIV-RNA level ≤400 copies/ml. Continued to have viral suppression
is defined as having a plasma HIV-RNA levelbelow 50 copies/ml
during successive measurements. The probability of experiencing
virological failure was significantly higher in children than in adults
(p<0.025)
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copies/ml was registered in 52/59 children (88%). Plasma
HIV-RNA levels remained under 400 copies/ml during
consecutive tests in 42/59 children (71%); 33/52 children
(63%) continued to have plasma HIV-RNA levels lower
than 50 copies/ml. Virological failure occurred in 12
children (20%). No data were available for the remaining
five children after reaching viral suppression. The proba-
bility of virological failure was significantly higher in
children than in adults (p=0.03, Fig. 3).
At one-year follow-up, the plasma HIV-RNA level was
lower than 400 copies/ml in 35 children (35/66 ITT=53%,
35/49 OT=71%) and lower than 50 copies/ml in 30 children
(30/66 ITT=45%, 30/49 OT=61%).
The mean CD4% increase was 12.6 (95% CI: 10.4–14.8,
p<0.001) at week 24 and 17.6 (95% CI: 14.1–21.1, p<0.001)
at week 52. The median CD4% at week 52 was 26.3 (IQR
20.0–33.0). Fifty-three children (80%) achieved a CD4% of
over 15 during the 52 weeks of follow-up and 53% of these
children attained this response within six weeks.
The children also gained weight during the study: the mean
weight gain was 2.2 kg (95% CI: 1.8–2.6, p<0.001) at week
24 and 3.6 kg (95% CI: 3.2–4.1, p<0.001) at week 52.
Predictors of efficacy in adults
A Karnofsky score ≤50, a BMI in the lowest quartile
(<17.1 kg/m2), and a CD4+ T-cell count <50/mm3 were all
associated with death in the univariate analysis. In
multivariate analysis, a Karnofsky score ≤50 at baseline
(95% CI: 0.09–0.32, p<0.001) and a CD4+ T-cell count
<50/mm3 (95% CI: 0.30–0.96, p=.04) remained as inde-
pendent predictors of death.
When the CD4 T-cell count remained below 200/mm3
during the year of observation, it was classified as a poor
immunological response. A Karnofsky score ≤50, a BMI in
the lowest quartile (<17.1 kg/m2), a CD4+ T-cell count
<50/mm3, and gender were associated with a poor
immunological response in both the univariate and multi-
variate analyses.
A CD4+ T-cell count <50/mm3 at baseline was also
associated with a statistically significant lower chance of
attaining a plasma HIV-RNA level lower than 50 copies/ml
(p=0.01).
Discussion
This study shows the feasibility of antiretroviral treatment
administered and monitored by general practitioners in a
primary healthcare setting in rural South Africa.
One year after the start of HAART, 89 of 609 adults
(15%) were lost to follow-up and 113 adults had died
(19%). Patients who did not show up for their scheduled
visits were actively followed-up. It seemed that patients
were often lost to follow-up due to labor migration, patient
preference for traditional healers, or the lack of means to
visit the clinic, but the exact numbers are unknown. There
is no reason to believe that a considerable number of
patients who were lost to follow-up had died, as their
baseline characteristics were similar to the rest of the
patients, apart from the baseline CD4+ T-cell count, which
was even higher in the patients who were lost to follow-up.
Immunologic outcomes were good: the mean CD4+ T-
cell count increase after one year was 236/mm3; previous
studies showed increases in mean CD4+ T-cell counts
ranging from 127/mm3 to 165/mm3 [5, 8–11].
In an on-treatment analysis at one-year follow-up, 83%
of the adult patients had a plasma HIV-RNA level lower
than 400 copies/ml and 70% of patients had a plasma HIV-
RNA level lower than 50 copies/ml; ITT was 55% and
46%, respectively. These results compare well to the results
of HAART in other settings. A historical meta-analysis of
clinical trials on NNRTI-based triple combination therapy
in antiretroviral-naïve patients in western settings showed a
plasma HIV-RNA level lower than 50 copies/ml after
48 weeks of treatment in 51% of patients (ITT) [5]. An
on-treatment analysis in a recent study on HAART in sub-
Sahara Africa showed a plasma HIV-RNA level lower than
50 copies/ml in 61% of patients after 48 weeks of therapy
(ITT 55%) [11]. Additionally, a meta-analysis of ten studies
on the efficacy of antiretroviral therapy in resource-poor,
urban settings showed similar virologic responses as that
observed in our study [17]. However, with the current
treatment options and low pill burden, outcomes in
developed countries are clearly better today [18, 19].
A recent comparative study examining viral suppression
in resource-poor and industrialized settings states that the
virologic responses are similar in these two settings when
correction is applied for the increased mortality rates in the
resource-poor settings during the first months of therapy
[20]. In our study, high mortality rates during the first
months of HAART were also observed [17, 21]. Patients
often sought help at an advanced stage of their disease; a
lower BMI and CD4+ T-cell count in men suggests that
men deferred coming to the clinic for even longer than
women. As a low Karnofsky score and a low baseline
CD4+ T-cell count were both independently associated with
death, this partly explains the relatively low survival
outcomes in the intention-to-treat analyses and points to a
need for earlier intervention.
Most studies on the virologic and immunologic efficacy
of HAART in sub-Saharan Africa were performed in urban
areas [6–9, 17], whereas the patients included in our study
lived in a rural environment with high unemployment rates
and a high HIV prevalence. This distinction is important, as
people living in remote areas often miss out on proper care
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and the process of scaling-up antiretroviral therapy in such
settings in sub-Saharan Africa meets different challenges
[10, 22]. A recent analysis showed that only 21% of the
people in Mpumalanga estimated to be in need of HAART
actually received it by the end of 2005 [23]. Apart from the
difference between urban and rural settings, the socio-
demographic data in our cohort (Table 1) are similar to
those found in a previous study from Cape Town [24].
Virological failure occurred more often in children
(20%) than in adults (10%). The reason for this finding is
unclear and needs further evaluation. It is possible that the
more complex dosing system using syrups instead of tablets
has led to mistakes by caregivers, but other factors, such as
specific adherence issues, may also have contributed to this
trend. A recent report on fixed-dose combination antire-
troviral therapy in children in resource-limited settings
showed similar results to our study regarding the median
CD4% gain [25]. The median follow-up time in that study
was only 6 months however, and no longitudinal viral load
testing was performed.
Independent predictors of death in adults were a low
Karnofsky score and a low CD4+ T-cell count at baseline.
In contrast to other studies [9, 10, 26, 27], we did not find a
significant correlation between low body weight and death.
All of the parameters included (low CD4+ T-cell count,
Karnofsky score, BMI, and gender) were independently
associated with a poor immunological response. The
breakdown analysis of CD4+ T-cell counts at baseline also
showed a clear trend towards higher survival rates with
increasing CD4+ T-cell counts (Table 2), supporting a
previous study which states that initiating HAART in
patients with CD4+ T-cell counts of over 200 is cost-
effective [28]. Another report found a low baseline CD4+
T-cell count to be predictive of a poor, virological outcome
[11]; this was confirmed by our data.
Unlike many other studies on HAART programs in
Africa [8–11], we measured the viral load in individual
patients throughout the treatment period. In contrast to the
opinion of some authors [29, 30], our data indicate that
longitudinal viral load testing is possible in developing
countries. In our opinion, viral load testing plays a
significant role in clinical decision-making during HAART.
The lack of routine viral load testing can lead to the
misdiagnosis of treatment failure and may result in
unnecessary regimen changes [31, 32]. An unexpected rise
in plasma HIV-RNA levels can indicate poor patient
adherence to treatment or viral resistance, and can be used
as a criterion for extra counseling or the changing of
treatment regimens.
The HAART program at the Ndlovu Medical Centre
provides extensive counseling before and during treatment.
Since most of the staff and all counselors are local people,
some HIV-positive themselves, they are able to comprehend
and discuss many problems that patients in the program
encounter. Given that adherence is vital to good treatment
outcomes [10, 33–35], we feel that the emphasis on
counseling and adherence were essential for the program’s
success. However, even in this closely monitored, strictly
counseled, and fully funded environment, with no monetary
costs for the patient, over 15% of patients were lost to
follow-up. Many domestic, social, and educational hurdles
still need to be overcome in order to achieve a more
favorable compliance rate.
We recognize that this study was limited by the relatively
short follow-up period.
In summary, this study shows that the treatment and
monitoring of HIV-infected patients by general practitioners
in rural areas in sub-Saharan Africa can result in good
virological, immunological, and clinical outcomes. In order
to achieve even more favorable results, early mortality
should be reduced and efforts should be made to start
HAART at an earlier stage of disease. These data support
the viability of and the need for large-scale initiatives to
address the enormous threat that AIDS has become
worldwide. Many questions remain unanswered, however,
and future research should focus on the long-term outcomes
of HAART and the possibilities for second and consecutive
lines of treatment in an attempt to predict and control viral
resistance.
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